| 产品描述: | HIF拮抗剂;HIF Antagonists;;InformationPT2399 PT2399 is a potent and orally available antagonist of HIF-2 that selectively disrupts the heterodimerization of HIF-2α with HIF-1β .TargetsHIF-2α ; HIF-1βIn vivoPT2399 dissociates HIF-2 (an obligatory heterodimer [HIF-2α/HIF-1β])14 in human Clear cell Renal Cell Carcinoma (ccRCC) suppressing tumorigenesis in 56% (10/18) lines. PT2399 has greater activity than sunitinib, is active in sunitinib-progressing tumors, and is better tolerated. Illustrating drug specificity, gene expression is largely unaffected by PT2399 in resistant tumors. Sensitive tumors exhibits a distinguishing gene expression signature, and generally higher HIF-2α levels. Prolonged PT2399 treatment leads to resistance. |
| 靶点: |
IC50: 6 nM (HIF-2α) |
| 体内研究: |
PT2399 降低肿瘤细胞密度并增加 RCC 小鼠的纤维化。 PT2399 (100 mg/kg;口服强饲法;每 12 小时一次) 比 SU 11248 更活跃,并抑制 RCC 荷瘤小鼠中几种 SU 11248 耐药肿瘤的肿瘤生长。 PT2399 直接抑制 HIF-2α 以靶向方式在原发性和转移性 pVHL 缺陷性 ccRCC 的临床前模型中导致肿瘤消退。 |
| 参考文献: |
1. Chen W, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016 Nov 3;539(7627):112-117. 2. Cho H, et al. On-Target Efficacy of a HIF2α Antagonist in Preclinical Kidney Cancer Models. Nature. Nature. 2016 Nov 3;539(7627):107-111. 3. Wehn PM, et al. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem. 2018 Nov 8;61(21):9691-9721. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.385 ml |
11.924 ml |
23.848 ml |
| 5 mM |
0.477 ml |
2.385 ml |
4.77 ml |
| 10 mM |
0.238 ml |
1.192 ml |
2.385 ml |
| 50 mM |
0.048 ml |
0.238 ml |
0.477 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |